Co-Authors
This is a "connection" page, showing publications co-authored by Teresa Lambe and Sandra Belij-Rammerstorfer.
Connection Strength
1.674
-
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. Commun Biol. 2021 07 26; 4(1):915.
Score: 0.240
-
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun. 2021 05 17; 12(1):2893.
Score: 0.236
-
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines. 2020; 5(1):69.
Score: 0.224
-
The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology. 2020 07; 160(3):223-232.
Score: 0.223
-
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 08 05; 184(16):4220-4236.e13.
Score: 0.059
-
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 Jun; 27(6):1116.
Score: 0.059
-
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 Jun; 27(6):1113.
Score: 0.059
-
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. ACS Cent Sci. 2021 Apr 28; 7(4):594-602.
Score: 0.059
-
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021 04 29; 184(9):2348-2361.e6.
Score: 0.058
-
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021 04 15; 184(8):2201-2211.e7.
Score: 0.058
-
Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2021 Feb; 590(7844):E24.
Score: 0.058
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 02; 27(2):279-288.
Score: 0.057
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 02; 27(2):270-278.
Score: 0.057
-
A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med (N Y). 2021 Mar 12; 2(3):243-262.e8.
Score: 0.057
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
Score: 0.057
-
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020 10; 586(7830):578-582.
Score: 0.056
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 08 15; 396(10249):467-478.
Score: 0.056